Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$36.75 USD
-2.12 (-5.45%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $36.70 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Dianthus Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
DNTH 36.75 -2.12(-5.45%)
Will DNTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Other News for DNTH
DNTH makes New 52 Week High on September 18
Is DNTH gaining bullish strength? New 52 Week Closing High shows up after advancing 3.76%
Clear Street Initiates Coverage on Dianthus Therapeutics (DNTH) with a 'Buy' Rating | DNTH ...
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc
Dianthus Therapeutics (DNTH) Receives a New Rating from Roth MKM